Recent Material Events - Accentia Biopharmace (ABPI)

Filing Date	Description
2008-08-04	On July 31, 2008, Biovest entered into an agreement (the “Extension Agreement”) with Laurus Master Fund, Ltd. (“Laurus”) and its affiliates, Valens U.S. SPV I, LLC, Valens Offshore SPV I, Ltd., Valens Offshore SPV II, Corp. and PS ...
2008-07-14	Prior to engaging Cherry Bekaert, the Company did not consult with Cherry Bekaert regarding the application of accounting principles to a specific completed or contemplated transaction or regarding the type of audit opinions that might be rendered by ...
2008-06-20	On June 18, 2008 the Company and Laurus Master Fund, Ltd. (“Laurus”) entered into agreements (the “Payoff and Amendment Agreements”) pursuant to which: (i) the Amended and Restated Secured Non-Convertible Revolving Note in the ori ...
2008-06-11	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized. ...
2008-05-23	This Current Report on Form 8-K sets forth statements that are not strictly historical in nature and such statements are referred to as “forward-looking statements.” The forward-looking statements in this Form 8-K include statements about o ...
2008-05-16	Accentia Biopharmaceuticals, Inc. Full Name of Registrant Former Name if Applicable 324 South Hyde Park Avenue, Suite 350 Address of Principal Executive Office (Street and Number) Tampa, Florida 33606 City, Sta ...
2008-04-30	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunder duly authorized. ...
2008-04-17	On April 15, 2008, Christopher C. Chapman, M.D. was appointed to the Board as a new director of the Company. The Board has determined that Dr. Chapman qualifies as an “independent” director within the meaning of applicable rules of the NASD ...
2008-04-11	The following information is being furnished under Item 7.01 of Form 8-K: the Form 8-K filed by the Company’s majority owned subsidiary, Biovest International, Inc. on April 11, 2008 regarding the Baltimore Sun ’s report on the first patien ...
2008-03-28	This Current Report on Form 8-K sets forth statements that are not strictly historical in nature and such statements are referred to as “forward-looking statements.” The forward-looking statements in this Form 8-K include statements about o ...